Sun Pharma reported a 15% YoY increase in Q3 net profit to ₹2,903.4 crore, with revenue rising 10% to ₹12,450 crore, driven by strong domestic and global sales.
Sun Pharmaceutical Industries Ltd, India’s largest pharmaceutical company based in Maharashtra, reported a 15% year-on-year (YoY) increase in its net profit for the third quarter (Q3) of the financial year 2024-25. The company’s net profit stood at ₹2,903.4 crore, while revenue rose 10% YoY to ₹12,450 crore, driven by strong sales in the domestic and global markets.
Q3 Financial Performance
Sun Pharma’s growth in Q3 was fueled by higher demand for its specialty and generic medicines, along with a strong performance in its key markets.
- Net Profit: ₹2,903.4 crore, up 15% YoY.
- Revenue: ₹12,450 crore, marking a 10% YoY growth.
- EBITDA: ₹3,500 crore, reflecting a margin expansion due to improved operational efficiency.
Growth Drivers
The pharmaceutical giant witnessed steady growth in its domestic and international segments. The Indian business contributed significantly to overall revenue, while the US and emerging markets also posted strong sales.
According to the company, higher sales of specialty drugs, better pricing strategies, and cost optimization contributed to the rise in profitability. The company’s dermatology and ophthalmology segments continued to perform well, strengthening its position in the global pharmaceutical industry.
Management’s Statement
Sun Pharma’s Managing Director, Dilip Shanghvi, stated that the company remains focused on expanding its specialty portfolio and strengthening its presence in key markets.
Our consistent growth reflects our strategic focus on specialty products, operational efficiency, and investments in innovation.”
Dilip Shanghvi, Managing Director of Sun Pharma
Sun Pharma expects sustained revenue growth in the coming quarters, backed by new product launches, research and development (R&D) investments, and global expansion strategies. With increasing demand for specialty and chronic care medicines, the company aims to maintain its growth trajectory in both domestic and international markets.
The strong Q3 performance reaffirms Sun Pharma’s position as a leading player in India’s pharmaceutical sector, with continued focus on innovation and expansion.
